Introduction
============

Type 2 diabetes mellitus (T2DM) is a chronic, systemic metabolic disease related to a variety of genetic and environmental factors ([@b1-mmr-21-06-2475]). Glycolipid metabolism disorder is a consequence of T2DM ([@b2-mmr-21-06-2475]). Normally, glycolipid metabolism is maintained in a stable state to provide energy, but disorders of glycolipid metabolism play a primary role in obesity and can increase the risk of various diseases, such as T2DM and vascular endothelial dysfunction, which are closely related to cardiovascular diseases ([@b3-mmr-21-06-2475]). Additionally, endothelial dysfunction can accelerate the pathological process of atherosclerosis, hypertension, T2DM and cerebrovascular disease ([@b4-mmr-21-06-2475]). Lipoprotein levels are also disturbed or complicated by glycolipid metabolism disorders, accompanied by a reduction in high-density lipoprotein (HDL) levels and an increase in total cholesterol (TC), triglyceride (TG) and low-density lipoprotein (LDL) levels ([@b5-mmr-21-06-2475]). Glycolipid metabolism disorders lead to insulin resistance and hyperlipidemia in T2DM mice ([@b2-mmr-21-06-2475]). Hyperlipidemia is classified as one of the major risk factors leading to cardiovascular disease ([@b6-mmr-21-06-2475]). In recent years, the impact of proinsulin C-peptide has been highlighted in the development of vascular disease. It plays an important role in both type 1 DM and T2DM ([@b7-mmr-21-06-2475]). A study among T2DM patients has shown that with the progression of diabetic retinopathy, there are lower levels of fasting and 2 h postprandial C-peptide compared with healthy individuals ([@b8-mmr-21-06-2475]). T2DM may progress to a late stage due to pancreatic β-cell demise and C-peptide deficiency ([@b9-mmr-21-06-2475]).

Cluster of differentiation (CD)36, a member of the scavenger receptor B (SRB) family, is the key transcription factor responsible for fatty acid synthesis, lipid uptake and catabolism, and is expressed predominantly by vascular cells ([@b10-mmr-21-06-2475]). CD36 has increasingly been considered as a possible biomarker for obesity, metabolic syndrome and T2DM ([@b11-mmr-21-06-2475]). CD36 protein serves a role in lipid metabolism and insulin resistance, and the expression of CD36 is inducible in obesity ([@b12-mmr-21-06-2475]). Studies in CD36-deficient humans and spontaneously hypertensive rats suggested that CD36 is responsible for hyperlipidemia and insulin resistance ([@b13-mmr-21-06-2475],[@b14-mmr-21-06-2475]). Inhibition of vascular endothelial cell-specific CD36 directly contributes to a reduction in lipid levels that correlates with improvement in the lipid markers LDL-r and TG ([@b15-mmr-21-06-2475],[@b16-mmr-21-06-2475]). CD36 not only has been implicated in mediating lipid internalization, but also can bind modified forms of LDL r and increase excessive cholesterol accumulation in macrophages ([@b17-mmr-21-06-2475]). CD36 is the main cause of atherosclerotic plaque formation induced by vascular lipid deposition ([@b18-mmr-21-06-2475]). However, the mechanism whereby CD36 controls glycolipid metabolism associated with T2DM remains to be elucidated.

Sterol regulatory element binding protein 2 (SREBP-2) is a main regulator that controls cholesterol biosynthesis gene expression ([@b19-mmr-21-06-2475]). CD36 can regulate SREBP-2 expression and subsequently stimulate the transcription of various lipogenic genes ([@b20-mmr-21-06-2475]). It has been reported that the SREBP cleavage-activating protein (SCAP)/SREBP2/LDL-r pathway plays a crucial role in regulating lipid droplets in numerous diseases ([@b21-mmr-21-06-2475]). This pathway regulates the transduction of a number of factors related to insulin sensitivity and glycolipid metabolism ([@b21-mmr-21-06-2475]). Lipid accumulation can be due to the upregulation of SREBP2, its target gene LDL-r and its regulatory gene scavenger receptor A(SRA), the subtype SRA1 ([@b22-mmr-21-06-2475]) was examined in the present study.

Epigallocatechin-3-gallate (EGCG) is a major polyphenol found in green tea. Preclinical studies in animals, and studies in cell line models and humans have reported the beneficial effects of EGCG ([@b23-mmr-21-06-2475]) on obesity-related parameters, including decreases in body weight ([@b24-mmr-21-06-2475]--[@b26-mmr-21-06-2475]), adipose mass ([@b24-mmr-21-06-2475]), food intake ([@b27-mmr-21-06-2475]) and total lipid, TC and TG levels in the liver and plasma, and improvement of glucose homeostasis ([@b24-mmr-21-06-2475],[@b25-mmr-21-06-2475],[@b28-mmr-21-06-2475]). Treatment of C57BL/6J mice with 0.32% dietary EGCG for 16 weeks has been shown to reduce body weight gain and markers of T2DM induced by a high-fat diet (HFD) ([@b24-mmr-21-06-2475]). EGCG reduces the reactive oxygen species content of the serum of obese KK-ay mice, as well as that of 3T3-L1 adipose cells, whilst also decreasing glucose levels and increasing glucose tolerance in animals ([@b29-mmr-21-06-2475]). Research has shown beneficial effects of the anti-lipid deposition activity of EGCG, and indicated that it may affect SREBP and CD36 in blood vessels ([@b30-mmr-21-06-2475]). Chen *et al* ([@b31-mmr-21-06-2475]), found that EGCG reduced oxidized LDL (ox-LDL) levels, decreased SRA expression (but not that of CD36), and suppressed ox-LDL uptake and foam cell formation in human macrophages in a dose-dependent manner. Furthermore, there are other mechanisms involved in the effects of EGCG on endothelial dysfunction. This includes prevention of oxidative injury in cultured endothelial cell lines via the downregulation of intercellular adhesion molecule 1 expression and 4-hydroxynonenal accumulation, and restoration of nitrite/nitrate levels and nitric oxide synthase 3 activity. EGCG can also protect endothelial cells via the downregulation of transforming growth factor-β and the Bax/Bcl-2/caspase 3 signaling pathway in the progression of diabetic nephropathy in rats ([@b32-mmr-21-06-2475],[@b33-mmr-21-06-2475]).

Therefore, the present study investigated the role of EGCG in regulating a macrovascular glycolipid metabolic disorder in T2DM, and the results may provide improved understanding of T2DM and its mechanisms.

Materials and methods
=====================

### Animals

A total of 67 C57BL6/J mice (male; 18--22 g; 4 weeks old) were purchased from Beijing Vital River Laboratory Animal Technology Co., Ltd. The mice were raised under controlled temperature (23±1°C) and humidity (50±5%) conditions with a 12 h light/dark cycle. The animals were allowed free access to drinking water and food. The animals were acclimated to the housing conditions for 7 days before the experiments. The health and behavior of each group of mice were observed daily. All experiments were approved by the Ethics Review Committee for Animal Experimentation of the Institute of Clinical Pharmacology, Kunming Medical University.

### Materials

The levels of TC (cat. no. CS0005; Sigma-Aldrich; Merck KGaA), TG (cat. no. MAK266; Sigma-Aldrich; Merck KGaA) and LDL-r (cat. no. RAB0707; Sigma-Aldrich; Merck KGaA) were measured using ELISA kits. An Oil Red O staining kit (cat. no. ab150678; Abcam) was also employed. The primary antibodies were anti-β-actin (cat. no. ab8227; 1:4,000; Abcam), anti-SRA1 (1:500; cat. no. sc-166139; Santa Cruz Biotechnology, Inc.), anti-CD36 (1:3,500; cat. no. ab133625; Abcam), anti-SREBP2 (1:3,000; cat. no. ab30682; Abcam) and anti-LDL-r (1:4,000; cat. no. ab52818; Abcam). The secondary antibodies used were Goat IgG horseradish peroxidase (HRP)-conjugated antibody (1:2,000; cat. no. HAF017; R&D Systems, Inc.) and Rabbit IgG HRP-conjugated antibody (1:2,000; cat. no. HAF008; R&D Systems, Inc.).

### Drugs

EGCG, a white powder with \>95% purity, was provided by the School of Pharmaceutical Sciences and Yunnan Key Laboratory of Pharmacology for Natural Products, Kunming Medical University. Pravastatin was obtained as a white power with \>97% purity from Sigma-Aldrich; Merck KGaA (cat. no. P4498).

### Experimental design

Diabetes was induced in 4-week-old male C57BL/6J mice as described previously ([@b12-mmr-21-06-2475]). Male mice were fed a HFD containing 22% fat, 48% carbohydrates and 20% protein blended with standard laboratory chow consisting of 5% fat, 53% carbohydrates and 23% protein for 4 weeks. After the period of dietary manipulation, animals were deprived of food for 12 h, and then the mice were injected intraperitoneally with a low dose of streptozotocin (STZ; 45 mg/kg; cat. no. 572201; Sigma-Aldrich; Merck KGaA), which was dissolved in 50 nm Na citrate buffer (pH 4.5). Thereafter, the animals had free access to water and standard food ([@b34-mmr-21-06-2475],[@b35-mmr-21-06-2475]). After 72 h of STZ administration, fasting blood sugar and insulin levels were measured with a reagent kit (cat. no. P006-1-1; Nanjing Jiancheng Bioengineering Institute Co., Ltd.). Mice were deprived for food for 6 h, and then fasting blood glucose levels were assessed, blood was drawn from the tail and body weight was measured weekly. Mice with fasting blood glucose ≥16.7 mmol/l were considered diabetic ([@b36-mmr-21-06-2475]). The diabetic mice were randomly divided into 5 groups (n=12/group): A diabetic model group, a pravastatin group (40 mg/kg body weight administered daily) and 3 EGCG groups. A total of 20 mice had succumbed to STZ toxicity during modeling ([@b37-mmr-21-06-2475]) so they were euthanized after reaching a humane endpoint, leaving only 8 in each diabetic model group. This level of mortality was accounted for in the ethical approval granted for this study. The health and behavior of each group of mice were observed daily.

EGCG was suspended in a 0.5% sodium carboxymethyl cellulose (CMC-Na) solution. Normal mice (n=7) and mice in the diabetic model groups (n=8/group) received CMC-Na. EGCG-treated diabetic mice received EGCG at 50, 100, or 200 mg/kg/day. All substances were given by oral gavage once daily for 6 weeks. Mouse weights were measured every 3 days. The duration of the animal experiment was 10 weeks. The longer the diabetic model mice were kept, the clearer their symptoms were (poor mental state, inactivity, reduced activity capacity, dull hair, eating more and urinating more), and the more evident their distress. The setting of the sampling time point was based on the relevant literature of EGCG ([@b38-mmr-21-06-2475],[@b39-mmr-21-06-2475]), and according to our previous preliminary experiments (data not shown), in order to ensure that the effects of EGCG could be evaluated while minimizing the distress of the experimental mice. All the procedures of the experiments in the present study were designed to reduce the suffering of experimental animals as much as possible in order to guarantee the stability of experimental results. At the end of the experiments, the animals were anesthetized with 1% sodium pentobarbital (50 mg/kg) via intraperitoneal injection. Blood was collected from the inferior vena cava into heparinized syringes, followed by centrifugation (1,300 × g, 20 min, 4°C). The serum was collected and stored in a deep freezer before analysis. Blood was taken from the inferior vena cava under anesthesia, and the hearts stopped beating and the mice succumbed after the blood was collected. The total volume of blood obtained from each mouse was 0.6±0.2 ml/mouse. After the blood was collected, each mouse experienced a 4--6% reduction in body weight. Additionally, respiratory arrest and cardiac arrest were monitored for 30 min to assess animal mortality. The abdominal aortas from each group were also obtained. All samples were kept at −80°C for mRNA, protein and oil red O staining analysis.

### Insulin tolerance test (ITT)

After 10 weeks of EGCG treatment, mice underwent an oral ITT ([@b40-mmr-21-06-2475]). Mice were deprived of food for 4 h, and the ITT was performed after intraperitoneal injection of insulin (0.75 UI/kg). Blood glucose concentrations were measured at 0 min, and then at 15, 30, 60, 90 and 120 min after insulin injection using a portable Contour^®^ glucose monitor (Bayer AG) and test strips. The concentration of insulin C-peptide in blood serum at 120 min was measured using a mouse insulin C-peptide radioimmunoassay kit (cat. no. DIC P00; R&D Systems, Inc.), according to the manufacturers protocols.

### Serum biochemical analysis

Serum was obtained from blood samples by centrifugation (1,350 × g, 4°C, 10 min) and stored at 80°C. Serum TG, TC and LDL-r levels were investigated with commercial assay kits and an automated Mindray BS-200 biochemistry analyzer instrument (Mindray Bio-Medical Electronics Co,. Ltd.).

### Reverse transcription-quantitative (RT-q)PCR

Total RNA was extracted from the tissue of each abdominal aorta using TRIzol^®^ (Thermo Fisher Scientific, Inc.). cDNA was synthesized from RevertAid First Strand cDNA Synthesis kit (cat. no. K1621; Thermo Fisher Scientific, Inc.) according to the manufacturers instructions. RT-qPCR was performed using SYBR Green PCR master mix (Applied Biosystems; Thermo Fisher Scientific, Inc.). Thermocycling conditions included, initial denaturation, 95°C for 10 min; followed by 40 cycles of 95°C for 5 sec and 60°C for 35 sec. The following primer sequences: CD36 forward, 5 CTGCTGTTCTTTGCCACGTC-3 and reverse, 5 CTGCTGTTCTTTGCCACGTC-3; SRA1 forward, 5 CCCCAGGTTCTTCACTACGCC-3 and reverse, 5 TCCTTATCCTGGGAGCCCTT-3; SREBP2 forward, 5 AGCATACCGCAAGGTGTTCC-3 and reverse, 5 CCAGGTGTCTACTTCTCCGTGT-3; LDL-r forward, 5 CAGCGTATCTGTGGCTGACA-3 and reverse, 5 AGTGTCGACTTCTCTAGGCT-3; β-actin forward, 5 GGCTGTGCTATCCCTGTACG-3 and reverse, 5 TTGATCTTCATTGTGCTGGGTG-3. Expression was analyzed with the 2^−∆∆Cq^ method ([@b41-mmr-21-06-2475]) and gene expression was presented as expression relative to that of the reference gene β-actin.

### Oil red O staining

Fresh-frozen optimal cutting temperature compound-embedded tissue sections were stained after 8-µm slices were obtained on a cryostat. The slides were placed in propylene glycol for 2 min and then incubated in oil red O solution for 6 min at room temperature. A mixture of 85% propylene glycol in distilled water was prepared, and the tissue sections were incubated in this mixture for 1 min at room temperature. The slides were rinsed in 2 changes of distilled water and then thoroughly rinsed in tap water at room temperature. For oil red O quantification, the slides were dried, and 250 µl of isopropanol was added, followed by incubation for 3 min at room temperature; the eluted solution was read at 510 nm using a Varioskan LUX multimode microplate reader (Thermo Fisher Scientific, Inc.).

### Western blot analysis

Protein from all frozen abdominal aorta samples was extracted with 1 ml of RIPA buffer (150 mM sodium chloride 1.0% NP40 or Triton X-100 Tris, pH 8.0). Protease and phosphatase inhibitor cocktails (cat. no. 78439; Thermo Fisher Scientific, Inc.) were added to the homogenization buffer. The concentration of protein in the supernatant of each sample was determined by using a Pierce™ Bradford assay kit (cat. no. 23200; Thermo Fisher Scientific, Inc.). The protein was then loaded using loading dye (40 µg protein/well) and separated in 8--12% SDS-PAGE gels. PVDF membranes were blocked with 0.5% BSA (cat. no. 17879-45-7; Guidechem), washed and incubated with the primary antibodies (1:1,000) described in the Materials section at 4°C overnight. The membranes were then blotted with the corresponding secondary antibody (1:2,000; cat. nos. HAF017 and HAF008; R&D Systems, Inc.) at room temperature for 1 h, and antigen-antibody interactions were detected by using Pierce ECL reagents (Thermo Fisher Scientific, Inc.) and quantified using a C-DiGit blot scanner (LI-COR Biosciences) and in-built Image Studio DiGit software (Flow max 2.82). Protein expression was presented as expression relative to that of the reference protein β-actin.

### Statistical analysis

Statistical analyses were performed using GraphPad Prism version 5.0 (GraphPad Software, Inc.) and P\<0.05 was considered to indicate a statistically significant difference. Students t-test was used to compare the two groups. One-way ANOVA followed by Tukeys post hoc test or repeated measures ANOVA was used to determine the significance of the differences between groups. The data are presented as the means ± standard error of the means unless otherwise stated.

Results
=======

### EGCG increases insulin sensitivity and decreases blood sugar levels in T2DM mice

To investigate whether EGCG reversed insulin resistance and blood sugar in T2DM mice, EGCG was administered to T2DM mice for 6 weeks; fasting blood glucose was measured and ITTs were performed. It was found that 72 h fasting blood glucose (normal 5.12±0.29 mg/ml vs. model 25.01±1.22 mg/ml; P\<0.001; [Fig. 1A](#f1-mmr-21-06-2475){ref-type="fig"}) was significantly increased in the model group after treatment with EGCG for 6 weeks. Blood glucose in the EGCG (200 mg/kg) group was significantly lower than in the model group at each tested time point (P\<0.01; Fig 1B), and the decrease occurred in a dose-dependent manner \[glucose in the model group (26.17±1.53 mg/ml) vs. the EGCG (200 mg/kg) group (7.76±1.09 mg/ml)\]. The results demonstrated that EGCG could decrease glucose levels in T2DM mice in a dose-dependent manner ([Fig. 1B](#f1-mmr-21-06-2475){ref-type="fig"}).

### The response to extrinsic insulin in the mice was investigated by an ITT

The results demonstrated that C-peptide levels in the EGCG group were significantly higher than in the model group at the 120-min time point (P\<0.001; [Fig. 1C](#f1-mmr-21-06-2475){ref-type="fig"}), and this increase occurred in a dose-dependent manner. The blood glucose levels at the 120 min after insulin injection in the EGCG (100 and 200 mg/kg) group were significantly lower than in the model group (P\<0.001; [Fig. 1D](#f1-mmr-21-06-2475){ref-type="fig"}). The results demonstrated that EGCG could decrease insulin resistance and ameliorate insulin sensitivity in T2DM mice.

### EGCG decreases the contents of TG, TC and LDL-r in T2DM mice

STZ-induced diabetic mice exhibited significantly increased blood serum levels of TG, TC and LDL r compared with normal mice (P\<0.001). EGCG (100, 200 mg/kg) decreased serum levels of TG, TC and LDL-r, as did pravastatin (P\<0.05; [Fig. 2A-C](#f2-mmr-21-06-2475){ref-type="fig"}).

### EGCG controls lipid deposition in the blood vessels of T2DM mice

The effects of EGCG on lipid deposition in blood vessels were investigated, as shown in [Fig. 3](#f3-mmr-21-06-2475){ref-type="fig"}. The lipid droplets in the blood vessels of the model group were irregular and larger, and they were significantly greater in number than those observed in the normal group (P\<0.001). EGCG (200 mg/kg) decreased the number of lipid droplets to a similar extent as pravastatin (P\>0.05).

### EGCG reduces the gene expression of SRA1, CD36, SREBP2 and LDL-r in the blood vessels of T2DM mice

All mRNA products of all tested genes were within normal values (Cq=16-30). The levels of the loading control and β-actin were constant in all tested samples. Significant increases in the relative mRNA expression of SRA1, CD36, SREBP2 and LDL-r were observed in the blood vessel samples obtained from STZ-induced mice compared with the normal mice. However, the EGCG group exhibited reduced gene expression of SRA1, CD36, SREBP2 and LDL r in blood vessels compared with the model group (P\<0.01 or P\<0.001; [Fig. 4](#f4-mmr-21-06-2475){ref-type="fig"}).

### EGCG inhibits the expression of SRA1, CD36, SREBP2, and LDL-r in diabetic mice

As shown in [Fig. 5](#f5-mmr-21-06-2475){ref-type="fig"}, the protein levels of SRA1, SREBP2 and LDL-r were increased in the diabetic mice compared with the normal group (P\<0.001). EGCG reduced the expression of SRA1 (P\<0.05), CD36 (P\<0.001), SREBP2 (P\<0.001) and LDL-r (P\<0.001) in a dose-dependent manner; EGCG downregulated the levels of SREBP2 and CD36 in a similar manner to pravastatin (P\>0.05).

Discussion
==========

Lipid metabolic dysfunction is associated with the development and progression of high-mortality diseases, including T2DM, as well as the subsequent associated cardiovascular and cerebrovascular pathologies ([@b42-mmr-21-06-2475]). Lipoprotein levels are also disturbed or complicated by lipid metabolism disorders, accompanied by a reduction in HDL levels, and an increase in TC, TG and LDL-r levels ([@b43-mmr-21-06-2475]). The present study identified that the levels of TC, TG and LDL were increased in HFD and STZ-induced T2DM mice. The serum TC, TG and LDL levels of the T2DM group were significantly higher compared with the normal group, showing that a hyperlipidemia T2DM mouse model had been successfully established. A previous clinical trial revealed that the serum levels of TG and LDL-r are significantly higher in T2DM patients with vascular lesions compared with T2DM patients without such complications ([@b44-mmr-21-06-2475]). The HFD and STZ-induced diabetic mice also demonstrated dyslipidemia, as evidenced by elevated levels of TC, LDL-r and TG, with a concomitant decrease in HDL, as observed in human T2DM ([@b45-mmr-21-06-2475]), which was consistent with the findings of the present study. Additionally, decreased expression of LDL-r and TG can reduce lipid accumulation in vascular lesions ([@b46-mmr-21-06-2475]). To observe this effect, lipid deposition in the vascular endothelium was measured by oil red O staining, and it was found that the lipid droplets in the blood vessels of the T2DM group were irregular and larger compared with those observed in the normal group.

The present study observed increased levels of TG and LDL-r in the serum of HFD/STZ-induced T2DM mice, as well as large amounts of lipid droplets deposited in vascular endothelial cells. The model mice treated with HFD/STZ had the same genetic background as the normal mice. This model involved the combination of HFD feeding to induce hyperlipidemia, hyperinsulinemia and glucose intolerance, and subsequent treatment with STZ ([@b47-mmr-21-06-2475]--[@b49-mmr-21-06-2475]), which resulted in a reduction in the number of functional β-cells. HFD/STZ-induced mice are designed to mimic the pathology of T2DM but on a shorter time scale than in humans. As pravastatin is not soluble in water, a suspension was made in 0.5% CMC-Na. In order to achieve solvent consistency, 0.5% CMC-Na was also used to dissolve the EGCG. CMC-Na is recognized as a solvent without any effect in pharmacological research.

In recent years, drugs used for the treatment of patients with T2DM, such as rosiglitazone and metformin, have been found to induce various side effects; in addition, they are unable to prevent angiopathy ([@b50-mmr-21-06-2475]). Due to the lack of effective and applicable pharmacological treatments for T2DM with hyperlipidemia and related vascular lesion dysfunctions, an increasing number of researchers are now studying traditional medicines. The investigation of the therapeutic functions of traditional medicinal herbs in T2DM presents promising potential.

TC, TG and LDL-r are the main markers of T2DM with angiopathy; a previous study indicated that they directly increase the risk of hyperlipidemia ([@b51-mmr-21-06-2475]). To investigate the protective mechanisms of EGCG, the expression of TC, TG and LDL-r in serum was tested. The results demonstrated that compared with the T2DM group, the EGCG treatment (200 mg/kg) group exhibited marked reductions in serum TC, TG and LDL levels. C-peptide is not affected by exogenous insulin, nor is it degraded by the liver ([@b52-mmr-21-06-2475]). It can directly reflect the secretion of endogenous insulin and the function of islet β-cells ([@b52-mmr-21-06-2475]). The ITT results of the present study demonstrated that EGCG (100 and 200 mg/kg) reduced blood glucose levels and promoted C-peptide levels. These results indicated that EGCG ameliorated the degree of fatty degeneration in vascular endothelial cells and modulated the expression levels of lipid metabolism genes in a dose-dependent manner.

To further confirm the protective mechanism of EGCG against vascular endothelial cell injury caused by lipid metabolism disorder in HFD and STZ-induced T2DM mice, gene and protein expression levels in vascular endothelial cells were detected. It was found that EGCG downregulated the expression of CD36 in a dose-dependent manner. CD36 has been found to act as a scavenger receptor for ox-LDL and as a cellular transporter of long-chain fatty acids ([@b53-mmr-21-06-2475]), and it is expressed on diverse cell types, including adipocytes, cardiac and skeletal myocytes, retinal pigment epithelial cells, platelets, mononuclear phagocytes and the microvascular endothelium ([@b54-mmr-21-06-2475]). In addition, a CD36 inhibitor can be used to lower lipid levels and reduce cholesterol accumulation *in vivo* ([@b55-mmr-21-06-2475]).

Yang *et al* ([@b56-mmr-21-06-2475]), identified enriched genes through Gene Ontology enrichment analyses. These genes were mainly related to biological processes such as steroid metabolism and lipid metabolism; their results indicated that CD36, SCAP, SREBP2 and LDL-r gene expression in the arterial endothelium may be a target of the lipid-reducing action of EGCG, which is consistent with the results of the present study. CD36 is a type of SRB, and scavenger receptor genes are closely related to lipid deposition in vascular endothelial cells and hyperlipidemia. The present study identified that the expression of CD36 was higher in the model group compared with the normal group at the mRNA level and the protein level, and that CD36 upregulated the expression of SREBP2 in the T2DM group. The oil red O staining revealed that the lipid droplets in the blood vessels of mice in the EGCG groups were fewer in number and smaller compared with the model group, particularly in the 200 mg/kg group. In addition, EGCG inhibited the expression of CD36, downregulated the expression of SREBP2 and decreased LDL-r levels.

At present, EGCG is widely used in research. A number of trials of patients with clinical tumors have proved that EGCG is safe and reliable, and oral administration is the main method of drug administration. For example, no adverse reactions were found following 1-year oral EGCG (300 mg/day) in patients with highly differentiated prostate cancer ([@b57-mmr-21-06-2475]). In the study on the safety of EGCG supplementation in postmenopausal women at high risk for breast cancer, only a few subjects who took 1,315 mg/day of green tea extract (with an EGCG content of 843 mg) experienced mild, transient adverse reactions ([@b58-mmr-21-06-2475]). The adverse reactions of EGCG were found to be mild in the dose expansion test of patients with estrogen receptor-negative breast cancer, and the main adverse reactions included nausea, heartburn, abdominal pain, headache, dizziness and myalgia ([@b59-mmr-21-06-2475]). In stage III non-small cell lung cancer treated with radiation and chemotherapy, and patients with breast cancer with neoadjuvant radiotherapy, giving EGCG was reported to be safe, and EGCG prevented radiation and chemotherapy injury, playing a positive role in promoting tissue repair ([@b60-mmr-21-06-2475],[@b61-mmr-21-06-2475]). These clinical trials of EGCG have shown its low toxicity and wide margin of safety.

Overall, the present study demonstrated that CD36 is a treatment target of EGCG in T2DM mice. EGCG downregulated glucose levels and upregulated C-peptide levels in T2DM mice, which may be associated with the protection of β-cell in the pancreas. In addition, EGCG ameliorates lipid metabolism disorders, perhaps by regulating the SREBP2/SCAP/LDL-r pathway, which is an effective way to control serum cholesterol synthesis levels. It was hypothesized that EGCG could regulate lipid metabolism in T2DM mice through CD36/SRA1/SREBP2/LDL-r pathways, and then reduce blood lipid deposition. Together, the results of the present work suggested that EGCG might be a promising natural hypoglycemic product for the prevention and treatment of lipid regulation disorders and the protection of vascular endothelial cells from lipid injury.
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![Effects of EGCG on the concentration of blood glucose and insulin resistance. (A) Effects of EGCG on the 72-h fasting glucose level. (B) Effects of EGCG on blood glucose after 6 weeks treatment with EGCG. EGCG (200 mg/kg) decreased blood glucose. (C) EGCG increased the C-peptide levels in T2DM mice at 120 min following insulin injection. (D) Blood glucose levels of all groups at 0, 15, 30, 60, 90 and 120 min following insulin injection. Comparisons for (A) were assessed with Student\'s t-test. Comparisons of (C) were assessed with one-way ANOVA followed by Tukey\'s post hoc test. \*\*P\<0.01, \*\*\*P\<0.001 vs. model group. Comparisons of (B and D) were assessed with repeated measures ANOVA. \*P\<0.05, \*\*P\<0.01, \*\*\*P\<0.001 vs. model at the respective time points. EGCG, epigallocatechin-3-gallate; T2DM, type 2 diabetes mellitus.](MMR-21-06-2475-g00){#f1-mmr-21-06-2475}

![Effects of EGCG on TG and LDL-r levels in serum. (A) Effects of EGCG on the concentration of TG. (B) Effects of EGCG on the concentration of TC. (C) Effects of EGCG on the concentration of LDL-r. The levels of serum TG and LDL-r were significantly increased in diabetic mice. Comparisons were assessed with one-way ANOVA followed by Tukey\'s post hoc test. \*P\<0.05, \*\*P\<0.01, \*\*\*P\<0.001 vs. model group. EGCG, epigallocatechin-3-gallate; TG, triglyceride; TC, total cholesterol; LDL-r, low-density lipoprotein receptor.](MMR-21-06-2475-g01){#f2-mmr-21-06-2475}

![EGCG repression controls lipid deposition in blood vessels of diabetic mice. Photomicrographs of oil red O-stained blood vessels in (A) the normal group, (B) the model group, (C) the EGCG (50 mg/kg) group, (D) the EGCG (100 mg/kg) group, (E) the EGCG (200 mg/kg) group and (F) the pravastatin group; magnification, 200×. (G) Quantification of oil red O-stained blood vessels for all groups. Comparisons were assessed with one-way ANOVA followed by Tukey\'s post hoc test. \*P\<0.05, \*\*P\<0.01, \*\*\*P\<0.001 vs. model group. EGCG, epigallocatechin-3-gallate.](MMR-21-06-2475-g02){#f3-mmr-21-06-2475}

![Relative mRNA expression of SRA1, SREBP2, LDL-r and CD36 in the blood vessels of STZ-induced treated mice. Significant increases in mRNA relative expression of SRA1 and CD36, SREBP2 and LDL-r were observed in the blood vessels from STZ-induced treated mice, compared with the normal mice. However, EGCG (100 mg/kg, 200 mg/kg) was able to reduce the gene expression of SRA1 and CD36, SREBP2 and LDL-r in blood vessels. Comparisons were assessed with one-way ANOVA followed by Tukey\'s post hoc test. \*\*P\<0.01, \*\*\*P\<0.001 vs. model group. SRA, scavenger receptor A; CD, cluster of differentiation; SREBP2, sterol regulatory element binding protein 2; LDL-r, low-density lipoprotein receptor; STZ, streptozotocin; EGCG, epigallocatechin-3-gallate.](MMR-21-06-2475-g03){#f4-mmr-21-06-2475}

![Protein levels of SRA1, CD36, SREBP2 and LDL-r. (A) Western blot analysis of SRA1, CD36, SREBP2 and LDL-r. (B) Quantification of the target protein level. Comparisons were assessed with one-way ANOVA followed by Tukey\'s post hoc test. \*\*P\<0.01, \*\*\*P\<0.001 vs. model group. SRA1, scavenger receptor A; CD, cluster of differentiation; SREBP2, sterol regulatory element binding protein 2; LDL-r, low-density lipoprotein receptor.](MMR-21-06-2475-g04){#f5-mmr-21-06-2475}
